Oncotelic Logo.png
Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO
June 10, 2020 08:00 ET | Mateon Therapeutics
The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of...
NewLink Genetics Corporation logo
NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commercialization of NLG207
December 23, 2019 16:05 ET | NewLink Genetics Corporation
AMES, Iowa, Dec. 23, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company has entered into an exclusive worldwide license agreement with Ellipses...
MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China
July 10, 2019 16:01 ET | MacroGenics, Inc.
ROCKVILLE, MD, and SHANGHAI, China, July 10, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative...
ChromaDex logo
ChromaDex Corp. and Nestlé Health Science Enter Global Commercial License and Supply Agreement for TRU NIAGEN®
December 20, 2018 16:05 ET | ChromaDex Corporation
LOS ANGELES, Dec. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a license and supply agreement with Nestlé Health Science (NHSc), a global leader...
The Premiere Group Acquires Derek Lam Beauty License
December 11, 2018 09:05 ET | The Premiere Group
New York, New York, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The Premiere Group, a wholly owned subsidiary of the Perfume Center of America Inc., has acquired the Derek Lam Beauty license, in a multi-year...
MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China
November 29, 2018 07:30 ET | MacroGenics, Inc.
Comprehensive collaboration across three MacroGenics’ pipeline programs to accelerate and expand ongoing developmentExpand Zai Lab’s late-stage clinical pipeline with margetuximab and obtain rights to...
Arbutus Biopharma Logo
Arbutus Announces Corporate Update and First Quarter 2018 Financial Results
May 03, 2018 16:00 ET | Arbutus Biopharma Corporation
Two Novel HBV Candidates Planned to Enter Clinical Development in 2018GalNAc Conjugated RNAi Agent Nominated to Enter IND-Enabling Studies Strategic Partnership with Roivant to Launch Genevant, an RNA...
Apricus logo
Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA
April 16, 2018 07:00 ET | Apricus Biosciences, Inc.
FDA Confirms Vitaros Regulatory Pathway  Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus...
Arbutus Biopharma Logo
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases
April 11, 2018 17:24 ET | Arbutus Biopharma Corporation
Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platformsGenevant will be led by...
Vera Bradley Announces New Licensing Agreement for Sleepwear/Loungewear
March 14, 2018 09:00 ET | Vera Bradley, Inc.
FORT WAYNE, Ind., March 14, 2018 (GLOBE NEWSWIRE) -- Vera Bradley, Inc. (Nasdaq:VRA) (“Vera Bradley” or the “Company”), the iconic accessories and lifestyle brand, today announced it has entered...